In a triumphant affirmation of its leadership in the global biotech industry, France’s HTL Biotechnology unveiled a new production line dedicated to producing sterile hyaluronic acid during the National Bioproduction and Biomedicines Day (JNBB). This occasion, held under the patronage of the President of the French Republic, resonates with HTL Biotechnology’s commitment to advancing therapeutic solutions by leveraging their three-decade-long expertise in biopolymer development.
HTL Biotechnology’s foray into sterile hyaluronic acid production marks a paradigm shift in the biomanufacturing landscape. This state-of-the-art process enables the convergence of hyaluronic acid and heat-sensitive molecules, which were previously incompatible due to traditional heat sterilization methods. Complemented by the mastery of aseptic processes, this innovation removes the risk of microbial contamination and ensures optimum pharmaceutical quality. This strategic move signifies a transformative step towards the development of new combined formulations, promising enhanced clinical benefits for patients across various fields, including ophthalmology and drug delivery.
This revolutionary production line is part of a €100 million strategic plan spanning 2022 to 2026, with a dedicated investment of €12 million. The initiative aims to propel HTL Biotechnology into new bioproduction frontiers while solidifying its position as a forerunner in the future applications of hyaluronic acid in healthcare. The company aims to kick-start production in 2026, following the qualification and validation of the industrial equipment.
To ensure the successful execution of this ambitious project, HTL Biotechnology has assiduously equipped its workforce with specialized training in aseptic procedures and handling the new product. A team of ten specialists, trained in the specific skills required for its production, will oversee the production line, ensuring adherence to the highest quality standards.
The new production unit not only expands HTL Biotechnology’s capabilities but also underscores its unwavering dedication to pioneering pharmaceutical-grade biopolymers. With a diverse portfolio of biopolymers such as Hyaluronic Acid, Polynucleotides, and soon recombinant human collagen, the company holds the baton in propelling healthcare advancements across multiple therapeutic areas.
HTL Biotechnology’s CEO, François Fournier, expressed his excitement about the promising future this investment unlocks for the company. He said, “The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction.”
This milestone signifies not just a leap for HTL Biotechnology but also a significant stride forward for the global biotech industry. As the demand for recombinant proteins surges, HTL Biotechnology’s strategic expansion and unwavering focus on research and development affirms its stature as a pivotal player in this rapidly evolving sector.
Read more from menafn.com
